Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose IL-2 vs SBRT + High Dose IL-2 in Metastatic Melanoma
NCT01416831Phase 2Active, not recruiting
- Start
- Jul 2011
- Primary completion
- Apr 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in melanoma. Started Jul 2011; status: active, not recruiting.
02
Drugs
aldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01416831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01416831.